Denali Therapeutics (DNLI) Stock Forecast & Price Target

Compare

737 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DNLI Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Denali

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DNLI Stock 12 Month Forecast

Average Price Target

$33.29

▲(113.40% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $33.29 with a high forecast of $40.00 and a low forecast of $27.00. The average price target represents a 113.40% change from the last price of $15.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","26":"$26","41":"$41","18.5":"$18.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,18.5,26,33.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,15.483076923076922,17.526153846153846,19.56923076923077,21.612307692307695,23.65538461538462,25.69846153846154,27.74153846153846,29.784615384615385,31.82769230769231,33.870769230769234,35.91384615384616,37.95692307692308,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,14.966923076923077,16.493846153846153,18.020769230769233,19.54769230769231,21.074615384615385,22.60153846153846,24.128461538461536,25.655384615384616,27.182307692307695,28.70923076923077,30.236153846153847,31.763076923076923,{"y":33.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.44,14.483076923076922,15.526153846153846,16.569230769230767,17.61230769230769,18.655384615384612,19.698461538461537,20.74153846153846,21.784615384615385,22.827692307692306,23.870769230769227,24.91384615384615,25.956923076923076,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.67,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.38,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.56,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$33.29

Lowest Price Target$27.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sean Laaman

Morgan Stanley

$33→$30

Buy

92.31%

Upside

Reiterated

08/18/25

Denali Therapeutics (DNLI) Receives a Buy from Morgan StanleyDNLI.O Denali Therapeutics Inc Overweight with price target change from 33.00 to 30.00.

Thomas Shrader

BTIG

$32

Buy

105.13%

Upside

Reiterated

08/17/25

BTIG Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Tazeen Ahmad

Bank of America Securities

$27

Buy

73.08%

Upside

Reiterated

08/14/25

Bank of America Securities Sticks to Their Buy Rating for Denali Therapeutics (DNLI)

Marc Goodman

Leerink Partners

$40

Buy

156.41%

Upside

Reiterated

08/13/25

Denali Therapeutics: Promising Developments and Financial Stability Drive Buy Rating

Andrew Fein

H.C. Wainwright

$32

Buy

105.13%

Upside

Reiterated

08/12/25

Denali Therapeutics: Advancements in CNS Delivery and Strategic Market Positioning Drive Buy RatingOur price target of $32 is based on an equally weighted composite of: (a) $37.34/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $6.57 discounted back to and (b) an NPV of $26/ share (discount rate 15%, growth rate 2%. Risks to our investment thesis and price target include: (1) failure of in clinical studies; (2) failure of to secure regulatory approval in the US and EU; and (3) failure of to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/or pricing).

Myles Minter

William Blair

―

Buy

―

Reiterated

08/12/25

Denali Therapeutics: Promising Developments and Regulatory Momentum Drive Buy Rating

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/11/25

Denali Therapeutics: Promising Pipeline and Regulatory Progress Justify Buy RatingWe see DNLI shares as undervalued for the broad potential of the company's TV platform. Remain Buy.

Paul Matteis

Stifel Nicolaus

$37

Buy

137.18%

Upside

Reiterated

07/07/25

Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)

Jay Olson

Oppenheimer

$35

Buy

124.36%

Upside

Reiterated

06/23/25

Oppenheimer Remains a Buy on Denali Therapeutics (DNLI)

Joel Beatty

Robert W. Baird

$30→$29

Buy

85.90%

Upside

Reiterated

05/08/25

Denali Therapeutics price target lowered to $29 from $30 at BairdDenali Therapeutics price target lowered to $29 from $30 at Baird

Mayank Mamtani

B.Riley Financial

$35→$30

Buy

92.31%

Upside

Reiterated

05/08/25

Denali Therapeutics price target lowered to $30 from $35 at B. RileyDenali Therapeutics price target lowered to $30 from $35 at B. Riley

Laura Chico

Wedbush

$32→$30

Buy

92.31%

Upside

Reiterated

05/07/25

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Dex Genotek

TR | OpenAI - 4o

―

Hold

―

Reiterated

04/21/25

AI Generated ArticleAI Generated Article

Joshua Schimmer

Cantor Fitzgerald

―

Buy

―

Upgraded

04/10/25

Denali Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldDenali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

David Hoang

Deutsche Bank

$31

Buy

98.72%

Upside

Initiated

02/11/25

Denali Therapeutics initiated with a Buy at Deutsche BankDenali Therapeutics initiated with a Buy at Deutsche Bank

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sean Laaman

Morgan Stanley

$33→$30

Buy

92.31%

Upside

Reiterated

08/18/25

Denali Therapeutics (DNLI) Receives a Buy from Morgan StanleyDNLI.O Denali Therapeutics Inc Overweight with price target change from 33.00 to 30.00.

Thomas Shrader

BTIG

$32

Buy

105.13%

Upside

Reiterated

08/17/25

BTIG Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

Tazeen Ahmad

Bank of America Securities

$27

Buy

73.08%

Upside

Reiterated

08/14/25

Bank of America Securities Sticks to Their Buy Rating for Denali Therapeutics (DNLI)

Marc Goodman

Leerink Partners

$40

Buy

156.41%

Upside

Reiterated

08/13/25

Denali Therapeutics: Promising Developments and Financial Stability Drive Buy Rating

Andrew Fein

H.C. Wainwright

$32

Buy

105.13%

Upside

Reiterated

08/12/25

Myles Minter

William Blair

―

Buy

―

Reiterated

08/12/25

Denali Therapeutics: Promising Developments and Regulatory Momentum Drive Buy Rating

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

08/11/25

Denali Therapeutics: Promising Pipeline and Regulatory Progress Justify Buy RatingWe see DNLI shares as undervalued for the broad potential of the company's TV platform. Remain Buy.

Paul Matteis

Stifel Nicolaus

$37

Buy

137.18%

Upside

Reiterated

07/07/25

Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)

Jay Olson

Oppenheimer

$35

Buy

124.36%

Upside

Reiterated

06/23/25

Oppenheimer Remains a Buy on Denali Therapeutics (DNLI)

Joel Beatty

Robert W. Baird

$30→$29

Buy

85.90%

Upside

Reiterated

05/08/25

Denali Therapeutics price target lowered to $29 from $30 at BairdDenali Therapeutics price target lowered to $29 from $30 at Baird

Mayank Mamtani

B.Riley Financial

$35→$30

Buy

92.31%

Upside

Reiterated

05/08/25

Denali Therapeutics price target lowered to $30 from $35 at B. RileyDenali Therapeutics price target lowered to $30 from $35 at B. Riley

Laura Chico

Wedbush

$32→$30

Buy

92.31%

Upside

Reiterated

05/07/25

Denali Therapeutics (DNLI) Gets a Buy from Wedbush

Dex Genotek

TR | OpenAI - 4o

―

Hold

―

Reiterated

04/21/25

AI Generated ArticleAI Generated Article

Joshua Schimmer

Cantor Fitzgerald

―

Buy

―

Upgraded

04/10/25

Denali Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldDenali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

David Hoang

Deutsche Bank

$31

Buy

98.72%

Upside

Initiated

02/11/25

Denali Therapeutics initiated with a Buy at Deutsche BankDenali Therapeutics initiated with a Buy at Deutsche Bank

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Denali Therapeutics

1 Month

xxx

Success Rate

10/13 ratings generated profit

Average Return

+8.12%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +8.12% per trade.

3 Months

xxx

Success Rate

9/16 ratings generated profit

Average Return

+14.99%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +14.99% per trade.

1 Year

Salveen RichterGoldman Sachs

Success Rate

5/11 ratings generated profit

Average Return

+29.13%

reiterated a buy rating 7 months ago

Copying Salveen Richter's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +29.13% per trade.

2 Years

xxx

Success Rate

5/18 ratings generated profit

Average Return

-8.05%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 27.78% of your transactions generating a profit, with an average return of -8.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNLI Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DNLI has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DNLI average Analyst price target in the past 3 months is 33.29.

Each month's total comprises the sum of three months' worth of ratings.

DNLI Financial Forecast

DNLI Earnings Forecast

Next quarter’s earnings estimate for DNLI is -$0.75 with a range of -$0.88 to -$0.66. The previous quarter’s EPS was -$0.72. DNLI beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year DNLI has Outperformed its overall industry.

DNLI Sales Forecast

Next quarter’s sales forecast for DNLI is $1.36M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $0.00. DNLI beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.93% of the time in the same period. In the last calendar year DNLI has Preformed in-line its overall industry.

DNLI Stock Forecast FAQ

What is DNLI’s average 12-month price target, according to analysts?

Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 33.29.

What is DNLI’s upside potential, based on the analysts’ average price target?

Denali Therapeutics has 113.40% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DNLI a Buy, Sell or Hold?

Denali Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Denali Therapeutics’s price target?

The average price target for Denali Therapeutics is 33.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $27.00. The average price target represents 113.40% Increase from the current price of $15.6.

What do analysts say about Denali Therapeutics?

Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of DNLI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Denali Therapeutics (DNLI) Stock Forecast & Price Target

DNLI Analyst Ratings

DNLI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Denali Therapeutics

DNLI Analyst Recommendation Trends

DNLI Financial Forecast

DNLI Earnings Forecast

DNLI Sales Forecast

DNLI Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts